NewsHK
The post-ICI second-line NSCLC market has become one of oncology's more contested fields, with antibody-drug conjugate regimens pressing hard on older cytotoxic backbones. Against that backdrop, BeyondSpring Inc.
(NASDAQ: BYSI) reported a net loss of $1.8 million for the quarter ended June 30, 2026, compared with $1.9 million in the same quarter of 2025, and disclosed that cash, cash equivalents, and short-term investments had fallen to $6.5 million from $12.6 million at year-end 2025.
Research and development expenses held flat at $1.0 million for the quarter. A $0.3 million uptick in drug manufacturing costs was offset by lower patent and personnel spending.
General and administrative costs edged down to $0.8 million from $0.9 million, as legal and consulting fees tied to accounting advisory and business development came in lighter.
Keep reading